Questcor Pharmaceuticals (QCOR) Slammed as Cerium Pharmaceuticals Granted FDA Orphan Drug Status
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Join SI Premium – FREE
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) is under heavy pressure early Friday which is related to reports Cerium Pharmaceuticals received FDA orphan drug designation for Synacthen Depot, the synthetic equivalent of Acthar.
Shares of QCOR last traded at $23.79, down 6.5 percent.
Shares of QCOR last traded at $23.79, down 6.5 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
